# Allergy Therapeutics to present at the H.C. Wainwright Global Investment Conference

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-to-present-at-the-h.c.wainwright-global-investment-conference-2/4121080757
- Published: 2022-09-05T07:05:16+01:00
- Author: Giles

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated commercial biotechnology company specialising in allergy vaccines,
has today announced that company management will participate in a fireside chat 
at the upcoming H.C. Wainwright Global Investment Conference being held September
12-14, 2022, in New York, NY and virtually.

The virtual fireside chat will be available to registered attendees of the conference
for on-demand viewing beginning September 12, 2022 at 9:00 a.m. ET/2:00 p.m. BST.
A replay of the presentation will be made available under the ‘Investors’ section
on Allergy Therapeutics’ website at [www.allergytherapeutics.com/investors/results-reports-and-presentations/](http://www.allergytherapeutics.com/investors/results-reports-and-presentations/).

Allergy Therapeutics is an international commercial biotechnology company focussed
on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy
vaccines that have the potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European countries and 
via distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree and house dust
mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in development.

Share on:
